Guidelines

Dr Apar Kishor Ganti Outlines the Effectiveness of Lurbinectedin and Benefits Over Competition

November 25th 2020, 4:30pm

Video

Lurbinectedin is being studied in a number of diseases, but in lung cancer it has a more favorable side effect profile compared with topotecan, said Apar Kishor Ganti, MD, University of Nebraska Medical Center.

With the Addition to NCCN Guidelines a Month After Approval, Lurbinectedin Addresses Unmet Need in SCLC

November 19th 2020, 6:45pm

By Jaime Rosenberg

Article

Before the approval of lurbinectedin, just 1 drug—topotecan—had approval for this indication, leaving these patients with few treatment options after progressing on their initial therapy.

Dr Apar Kishor Ganti on How Lurbinectedin Improves Outcomes in SCLC

November 13th 2020, 1:00pm

Video

Small cell lung cancer is an aggressive disease that has had few treatment options before lurbinectedin, said Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology & Hematology, University of Nebraska Medical Center.

A Look at Currently Available Data on Recently Approved, NCCN-Recommended Lurbinectedin for SCLC

November 11th 2020, 5:00pm

By Jaime Rosenberg

Article

In June, lurbinectedin became just the second approved treatment for patients whose metastatic small cell lung cancer (SCLC) has progressed on or after platinum-based chemotherapy, joining topotecan.

Dr Apar Kishor Ganti Explains Why Lurbinectedin Is Exciting for Patients With SCLC

November 1st 2020, 2:00pm

Video

With few treatment options in small cell lung cancer, lurbinectedin was quickly added to the National Comprehensive Cancer Network’s guidelines after the FDA approved it, said Apar Kishor Ganti, MD, of University of Nebraska Medical Center.